Profound Medical (NASDAQ:PROF) & Aptorum Group (NASDAQ:APM) Financial Analysis

Aptorum Group (NASDAQ:APM) and Profound Medical (NASDAQ:PROF) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Institutional & Insider Ownership

3.8% of Aptorum Group shares are held by institutional investors. Comparatively, 47.9% of Profound Medical shares are held by institutional investors. 64.0% of Aptorum Group shares are held by insiders. Comparatively, 1.5% of Profound Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Aptorum Group and Profound Medical”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptorum Group	$430,000.00	11.56	-$4.27 million	N/A	N/A
Profound Medical	$10.68 million	22.43	-$27.82 million	($1.34)	-4.93

Aptorum Group has higher earnings, but lower revenue than Profound Medical.

Analyst Recommendations

This is a summary of current recommendations for Aptorum Group and Profound Medical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptorum Group	1	0	0	0	1.00
Profound Medical	1	0	1	0	2.00

Profound Medical has a consensus price target of $12.00, suggesting a potential upside of 81.82%. Given Profound Medical’s stronger consensus rating and higher probable upside, analysts clearly believe Profound Medical is more favorable than Aptorum Group.

Volatility & Risk

Aptorum Group has a beta of 0.11, suggesting that its share price is 89% less volatile than the S&P 500. Comparatively, Profound Medical has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500.

Profitability

This table compares Aptorum Group and Profound Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aptorum Group	N/A	N/A	N/A
Profound Medical	-275.16%	-86.18%	-70.55%

Summary

Profound Medical beats Aptorum Group on 7 of the 12 factors compared between the two stocks.

About Aptorum Group

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.